Various partners marketing Remsima globally

Celltrion is a leading South Korean biopharmaceutical company specializing in the development and manufacture of biosimilars and innovative biologics. The company gained global recognition as the developer of Remsima (infliximab), the world's first monoclonal antibody biosimilar approved by major regulatory agencies like the EMA and FDA. Celltrion operates a large-scale manufacturing infrastructure and has expanded its portfolio to include treatments for oncology, autoimmune diseases, and infectious diseases. Following the merger with Celltrion Healthcare, the company has transitioned into a vertically integrated global pharma player, managing everything from R&D to direct global sales and distribution.